Otsuka Plans ¥1 Trillion IPO To Expand Beyond Abilify And Soyjoy
This article was originally published in PharmAsia News
Executive Summary
Aiming at expanding beyond its blockbuster schizophrenia drug and widely popular personal care products, Japan's fifth-largest drug maker Otsuka Pharmaceutical is reportedly preparing an initial public offering in Tokyo estimated to be valued at over ¥1 trillion ($12 billion) based on calculations of the stock option exercise price, making Otsuka one of the largest Japanese drug makers to go public in a decade